Natera and Eledon Pharmaceuticals partnered to use Natera’s Prospera donor-derived cell-free DNA (dd-cfDNA) test as an exclusive longitudinal monitoring assay in Eledon’s Phase III kidney transplant trial. The study will evaluate Eledon's tegoprubart, an investigational anti-CD40L antibody aimed at preventing organ rejection. Prospera will be used across an enrollment target of about 600 kidney transplant recipients across more than 100 transplant centers globally. Natera said the test will apply a two-threshold algorithm combining the relative fraction of dd-cfDNA with calculated total dd-cfDNA amount for ongoing surveillance. Natera positioned the approach as a first large-scale therapeutic trial incorporation of Prospera for longitudinal monitoring in transplantation, aiming to generate prospective datasets linking molecular surveillance to allograft injury dynamics. The trial is scheduled to begin later this year, with the outcome likely to influence future use of dd-cfDNA assays for guiding immunosuppression intensity in real-world transplant care.